Buffington Mohr McNeal’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$285K Sell
11,262
-1,200
-10% -$31.4K 0.06% 92
2024
Q4
$331K Buy
+12,462
New +$338K 0.05% 108
2024
Q1
Sell
-17,650
Closed -$508K 133
2023
Q4
$508K Buy
17,650
+5,200
+42% +$157K 0.1% 91
2023
Q3
$413K Buy
12,450
+1,114
+10% +$39.4K 0.09% 97
2023
Q2
$416K Sell
11,336
-3,350
-23% -$130K 0.09% 94
2023
Q1
$599K Sell
14,686
-693
-5% -$29.9K 0.14% 89
2022
Q4
$788K Sell
15,379
-1,499
-9% -$71.9K 0.18% 77
2022
Q3
$739K Buy
16,878
+93
+0.6% +$4.52K 0.18% 80
2022
Q2
$880K Buy
16,785
+1,547
+10% +$78.8K 0.19% 77
2022
Q1
$789K Buy
15,238
+1
+0% +$52 0.15% 85
2021
Q4
$900K Buy
15,237
+3,087
+25% +$153K 0.15% 85
2021
Q3
$523K Buy
12,150
+1
+0% +$44 0.1% 92
2021
Q2
$476K Hold
12,149
0.09% 100
2021
Q1
$440K Buy
12,149
+2,819
+30% +$100K 0.09% 99
2020
Q4
$343K Sell
9,330
-410
-4% -$15K 0.08% 102
2020
Q3
$339K Sell
9,740
-1,054
-10% -$37K 0.09% 100
2020
Q2
$335K Buy
10,794
+167
+2% +$5.67K 0.09% 98
2020
Q1
$329K Hold
10,627
0.11% 94
2019
Q4
$395K Sell
10,627
-258
-2% -$9.19K 0.11% 97
2019
Q3
$371K Buy
10,885
+439
+4% +$16K 0.11% 99
2019
Q2
$429K Sell
10,446
-35
-0.3% -$1.39K 0.13% 96
2019
Q1
$422K Buy
10,481
+368
+4% +$14.7K 0.14% 97
2018
Q4
$419K Hold
10,113
0.17% 95
2018
Q3
$423K Buy
10,113
+29
+0.3% +$1.12K 0.15% 98
2018
Q2
$347K Buy
10,084
+45
+0.4% +$1.54K 0.13% 106
2018
Q1
$338K Hold
10,039
0.13% 103
2017
Q4
$345K Hold
10,039
0.13% 102
2017
Q3
$339K Sell
10,039
-2,319
-19% -$74.5K 0.13% 106
2017
Q2
$394K Sell
12,358
-1,866
-13% -$58.8K 0.16% 104
2017
Q1
$462K Buy
14,224
+2,320
+19% +$73.1K 0.2% 83
2016
Q4
$367K Sell
11,904
-74
-0.6% -$2.26K 0.14% 91
2016
Q3
$384K Sell
11,978
-271
-2% -$9.06K 0.16% 90
2016
Q2
$409K Hold
12,249
0.18% 89
2016
Q1
$344K Buy
12,249
+345
+3% +$9.86K 0.15% 104
2015
Q4
$365K Buy
+11,904
New +$374K 0.2% 72

Other funds holding PFE

Buffington Mohr McNeal's PFE Position: Q1 2025 in Review

Buffington Mohr McNeal reduced its Pfizer (PFE) stake by 9.6% in Q1 2025, selling an estimated $31.4K and leaving 11,262 shares worth $285K. The position accounts for 0.06% of the portfolio, ranked #92.

Buffington Mohr McNeal first reported a position in PFE in Q4 2015 and has held it in 35 quarters since. The position peaked at $900K in Q4 2021. 2,931 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Buffington Mohr McNeal held 11,262 shares of Pfizer worth $285K as of Q1 2025.
  • Buffington Mohr McNeal sold 1,200 Pfizer shares in Q1 2025, an estimated $31.4K.
  • Pfizer made up 0.06% of Buffington Mohr McNeal's portfolio in Q1 2025, its #92 holding.
  • Buffington Mohr McNeal first reported a position in Pfizer in Q4 2015 and has held it in 35 quarters since.
  • Buffington Mohr McNeal's Pfizer position peaked at $900K in Q4 2021.
  • 2,931 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Buffington Mohr McNeal's 13F filing for Q1 2025, filed 28 Apr 2025.